Over the past year, headlines across industry and consumer media have highlighted FDA warnings on the dangers of gadolinium-based contrast agents. To date, it has become common knowledge and a FDA black box warning that gadolinium-based agents run the risk of causing Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD).

Advances in molecular imaging, specifically through the discovery of new molecular imaging agents and developments in the technologies that enable their visualization have opened up new possibilities for the early detection of disease as well as personalized medicine.